Novavax appoints senior vp of business development


Russell ‘Rip’ Wilson takes the role at US biopharmaceutical firm

US biopharmaceutical firm Novavax has appointed Russell ‘Rip’ Wilson as senior vice president of business development. He takes responsibility for developing business alliances, licensing arrangements, and partnering opportunities with pharmaceutical companies and government agencies.

Wilson was most recently chief financial officer at Supernus Pharmaceuticals. He was previously senior vice president, chief financial officer and general counsel of Iomai Corporation, which was acquired in 2008 by Intercell. He was also the acting general counsel of North American Vaccine, until its acquisition by Baxter International in 2000.